MedTrace Logo

Tanezumab In Osteoarthritis Of The Hip Or Knee

NCT00985621 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 614

Last updated 2021-05-14

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis

Conditions

Interventions

BIOLOGICAL

tanezumab 10 mg

tanezumab 10 mg one dose at weeks 0 and 8

BIOLOGICAL

tanezumab 5 mg

tanezumab 5 mg one dose at weeks 0 and 8

DRUG

oxycodone

oxycodone CR, 10-40 mg q12h

OTHER

placebo

placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-30
Primary Completion
2010-12-13
Completion
2011-02-04

Countries

  • United States
  • Austria
  • Denmark
  • Germany
  • Poland
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00985621 on ClinicalTrials.gov